Considering that specific inhibition by antisense oligonucleotides against DNMT1 leads to restart expression of ERα in negative BC cells, this gene can be an interesting target to evaluate for restoring ERα expression in order to promote endocrine therapy efficiency [80]. The gene discussed is ESR1; the disease is breast cancer.